Oxford Biomedica PLC REPLACEMENT: Total Voting Rights (7685X)

TIDMOXB

RNS Number : 7685X

Oxford Biomedica PLC

01 May 2019

Oxford Biomedica

Total Voting Rights

The 'Total Voting Rights' announcement released today at 11:33 under RNS No 7565X contained an incorrect figure and is replaced by this announcement.

Oxford, UK - 1 May 2019: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 30 April 2019 consisted of 68,863,354 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 68,863,354.

The above figure (68,863,354) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure and Transparency Rules.

-Ends-

 
 For further information, please contact: 
  Oxford Biomedica plc:                      Tel: [phone] 
   Stuart Paynter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

TVRCKDDQDBKDCPK

(END) Dow Jones Newswires

May 01, 2019 07:52 ET (11:52 GMT)